CLINICAL_TRIALS
trial_result
· 2020-09-01
Clinical Trial Update: Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas [Phase 2]
Summary
Phase 2 clinical trial update for Zevalin (ibritumomab tiuxetan) in early-stage indolent lymphomas has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-01